These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Assessment of hallucinations in Parkinson's disease using a novel scale. Wada-Isoe K; Ohta K; Imamura K; Kitayama M; Nomura T; Yasui K; Nakaso K; Nakashima K Acta Neurol Scand; 2008 Jan; 117(1):35-40. PubMed ID: 18095953 [TBL] [Abstract][Full Text] [Related]
43. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Finkel SI Clin Ther; 2004 Jul; 26(7):980-90. PubMed ID: 15336465 [TBL] [Abstract][Full Text] [Related]
44. [Neuropsychiatric problems in patients with Parkinson's disease]. Zhou MZ; Liu ZG; Gan J; Chen W; Lu LX; Wu JY Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(21):1442-5. PubMed ID: 18953846 [TBL] [Abstract][Full Text] [Related]
45. Neuropsychiatric symptoms in Parkinson's disease with mild cognitive impairment and dementia. Leroi I; Pantula H; McDonald K; Harbishettar V Parkinsons Dis; 2012; 2012():308097. PubMed ID: 22970412 [TBL] [Abstract][Full Text] [Related]
46. Prevalence and treatment pattern of Parkinson's disease dementia in Korea. Oh YS; Kim JS; Park IS; Shim YS; Song IU; Park JW; Lee PH; Lyoo CH; Ahn TB; Ma HI; Kim YD; Koh SB; Lee SJ; Lee KS Geriatr Gerontol Int; 2016 Feb; 16(2):230-6. PubMed ID: 25656841 [TBL] [Abstract][Full Text] [Related]
47. Neuropsychiatric symptoms in dementia may predict caregiver burden: a Sicilian exploratory study. Torrisi M; De Cola MC; Marra A; De Luca R; Bramanti P; Calabrò RS Psychogeriatrics; 2017 Mar; 17(2):103-107. PubMed ID: 27411501 [TBL] [Abstract][Full Text] [Related]
51. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863 [TBL] [Abstract][Full Text] [Related]
53. An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson's disease. Hatano T; Hattori N; Kawanabe T; Terayama Y; Suzuki N; Iwasaki Y; Fujioka T; J Neural Transm (Vienna); 2014; 121(3):275-81. PubMed ID: 24169925 [TBL] [Abstract][Full Text] [Related]
54. Predictors of depressive symptoms among spouse caregivers in Parkinson's disease. Fernandez HH; Tabamo RE; David RR; Friedman JH Mov Disord; 2001 Nov; 16(6):1123-5. PubMed ID: 11748746 [TBL] [Abstract][Full Text] [Related]
55. [Influence of leukoaraiosis on the cognition of patients with Parkinson disease]. Wang L; Zhu XQ; Jiang CJ; Chen XW; Sun ZW Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(3):177-81. PubMed ID: 23570589 [TBL] [Abstract][Full Text] [Related]
56. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Thomas AJ; Burn DJ; Rowan EN; Littlewood E; Newby J; Cousins D; Pakrasi S; Richardson J; Sanders J; McKeith IG Int J Geriatr Psychiatry; 2005 Oct; 20(10):938-44. PubMed ID: 16163744 [TBL] [Abstract][Full Text] [Related]
57. Safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease-Results of a multicenter open trial. Kashihara K; Maeda T; Yoshida K Neuropsychopharmacol Rep; 2022 Jun; 42(2):135-141. PubMed ID: 35226404 [TBL] [Abstract][Full Text] [Related]
58. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Rodda J; Morgan S; Walker Z Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824 [TBL] [Abstract][Full Text] [Related]
59. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy. Modrego PJ; Pina MA; Fayed N; Díaz M CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455 [TBL] [Abstract][Full Text] [Related]
60. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Minett TS; Thomas A; Wilkinson LM; Daniel SL; Sanders J; Richardson J; Littlewood E; Myint P; Newby J; McKeith IG Int J Geriatr Psychiatry; 2003 Nov; 18(11):988-93. PubMed ID: 14618549 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]